Skip to main content
Top
Published in: Diabetologia 1/2010

Open Access 01-01-2010 | Article

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

Authors: E. Ritz, G. C. Viberti, L. M. Ruilope, A. J. Rabelink, J. L. Izzo Jr, S. Katayama, S. Ito, A. Mimran, J. Menne, L. C. Rump, A. Januszewicz, H. Haller

Published in: Diabetologia | Issue 1/2010

Login to get access

Abstract

Aims/hypothesis

In contrast to microalbuminuric type 2 diabetic patients, the factors correlated with urinary albumin excretion are less well known in normoalbuminuric patients. This may be important because even within the normoalbuminuric range, higher rates of albuminuria are known to be associated with higher renal and cardiovascular risk.

Methods

At the time of screening for the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study, the urinary albumin/creatinine ratio (UACR) was 0.44 mg/mmol in 4,449 type 2 diabetic patients. The independent correlates of UACR were analysed.

Results

Independent correlates of UACR during baseline were (in descending order): night-time systolic BP (r s = 0.19); HbA1c (r s = 0.18); mean 24 h systolic BP (r s = 0.16); fasting blood glucose (r s = 0.16); night-time diastolic BP (r s = 0.12); office systolic BP, sitting (r s = 0.11), standing (r s = 0.10); estimated GFR (r s = 0.10); heart rate, sitting (r s = 0.10); haemoglobin (r s = −0.10); triacylglycerol (r s = 0.09); and uric acid (r s = −0.08; all p ≤ 0.001). Significantly higher albumin excretion rates were found for the following categorical variables: higher waist circumference (more marked in men); presence of the metabolic syndrome; smoking (difference more marked in males); female sex; antihypertensive treatment; use of amlodipine; insulin treatment; family history of diabetes; and family history of cardiovascular disease (more marked in women).

Conclusions/interpretation

Although observational correlations do not prove causality, in normoalbuminuric type 2 diabetic patients the albumin excretion rate is correlated with many factors that are potentially susceptible to intervention.

Trial registration:

ClinicalTrials.gov ID no.: NCT00185159

Funding:

This study was sponsored by Daichii-Sankyo.
Literature
1.
go back to reference Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D (2006) Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 15:631–636CrossRefPubMed Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D (2006) Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 15:631–636CrossRefPubMed
2.
go back to reference Senator H (1884) Albuminuria in health and disease. The New Sydenham Society, London Senator H (1884) Albuminuria in health and disease. The New Sydenham Society, London
3.
go back to reference Mogensen CE (1971) Urinary albumin excretion in diabetes. Lancet 2:601–602PubMed Mogensen CE (1971) Urinary albumin excretion in diabetes. Lancet 2:601–602PubMed
4.
go back to reference Mogensen C (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356–360PubMedCrossRef Mogensen C (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356–360PubMedCrossRef
5.
go back to reference Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1:1430–1432CrossRefPubMed Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1:1430–1432CrossRefPubMed
6.
go back to reference Wachtell K, Ibsen H, Olsen MH et al (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Ann Intern Med 139:901–906PubMed Wachtell K, Ibsen H, Olsen MH et al (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Ann Intern Med 139:901–906PubMed
7.
go back to reference Rachmani R, Levi Z, Lidar M, Slavachevski I, Half-Onn E, Ravid M (2000) Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract 49:187–194CrossRefPubMed Rachmani R, Levi Z, Lidar M, Slavachevski I, Half-Onn E, Ravid M (2000) Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract 49:187–194CrossRefPubMed
8.
go back to reference Arnlov J, Evans JC, Meigs JB et al (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112:969–975CrossRefPubMed Arnlov J, Evans JC, Meigs JB et al (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112:969–975CrossRefPubMed
9.
10.
go back to reference Gallego PH, Gilbey AJ, Grant MT et al (2005) Early changes in 24-hour ambulatory blood pressure are associated with high normal albumin excretion rate in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 18:879–885PubMed Gallego PH, Gilbey AJ, Grant MT et al (2005) Early changes in 24-hour ambulatory blood pressure are associated with high normal albumin excretion rate in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 18:879–885PubMed
11.
go back to reference Perrin NE, Torbjornsdotter TB, Jaremko GA, Berg UB (2004) Follow-up of kidney biopsies in normoalbuminuric patients with type 1 diabetes. Pediatr Nephrol 19:1004–1013CrossRefPubMed Perrin NE, Torbjornsdotter TB, Jaremko GA, Berg UB (2004) Follow-up of kidney biopsies in normoalbuminuric patients with type 1 diabetes. Pediatr Nephrol 19:1004–1013CrossRefPubMed
12.
go back to reference Stone ML, Craig ME, Chan AK, Lee JW, Verge CF, Donaghue KC (2006) Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: a longitudinal study. Diabetes Care 29:2072–2077CrossRefPubMed Stone ML, Craig ME, Chan AK, Lee JW, Verge CF, Donaghue KC (2006) Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: a longitudinal study. Diabetes Care 29:2072–2077CrossRefPubMed
13.
go back to reference Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N (2004) Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 47:1020–1028CrossRefPubMed Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N (2004) Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 47:1020–1028CrossRefPubMed
14.
go back to reference Hovind P, Tarnow L, Rossing P et al (2004) Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 328:1105–1109CrossRefPubMed Hovind P, Tarnow L, Rossing P et al (2004) Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 328:1105–1109CrossRefPubMed
15.
go back to reference Yamada T, Komatsu M, Komiya I et al (2005) Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa Study. Diabetes Care 28:2733–2738CrossRefPubMed Yamada T, Komatsu M, Komiya I et al (2005) Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa Study. Diabetes Care 28:2733–2738CrossRefPubMed
16.
go back to reference Haller H, Viberti GC, Mimran A et al (2006) Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study. J Hypertens 24:403–408CrossRefPubMed Haller H, Viberti GC, Mimran A et al (2006) Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study. J Hypertens 24:403–408CrossRefPubMed
17.
go back to reference Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951CrossRefPubMed Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951CrossRefPubMed
18.
go back to reference Strippoli GF, Craig M, Navaneethan SD, Craig JC (2006) Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006, CD006257 Strippoli GF, Craig M, Navaneethan SD, Craig JC (2006) Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006, CD006257
19.
go back to reference Strain WD, Chaturvedi N, Dockery F et al (2006) Increased arterial stiffness in Europeans and African Caribbeans with type 2 diabetes cannot be accounted for by conventional cardiovascular risk factors. Am J Hypertens 19:889–896CrossRefPubMed Strain WD, Chaturvedi N, Dockery F et al (2006) Increased arterial stiffness in Europeans and African Caribbeans with type 2 diabetes cannot be accounted for by conventional cardiovascular risk factors. Am J Hypertens 19:889–896CrossRefPubMed
20.
go back to reference Lurbe E, Redon J, Kesani A et al (2002) Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347:797–805CrossRefPubMed Lurbe E, Redon J, Kesani A et al (2002) Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347:797–805CrossRefPubMed
21.
go back to reference Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis Hansen P, Parving HH (2005) Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 68:1250–1257CrossRefPubMed Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis Hansen P, Parving HH (2005) Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 68:1250–1257CrossRefPubMed
22.
go back to reference Afsar B, Sezer S, Elsurer R, Ozdemir FN (2007) Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus? Blood Press Monit 12:133–139CrossRefPubMed Afsar B, Sezer S, Elsurer R, Ozdemir FN (2007) Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus? Blood Press Monit 12:133–139CrossRefPubMed
23.
go back to reference Tamura K, Tsurumi Y, Sakai M et al (2007) A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 29:31–42CrossRefPubMed Tamura K, Tsurumi Y, Sakai M et al (2007) A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 29:31–42CrossRefPubMed
24.
go back to reference Nakano S, Ito T, Furuya K et al (2004) Ambulatory blood pressure level rather than dipper/nondipper status predicts vascular events in type 2 diabetic subjects. Hypertens Res 27:647–656CrossRefPubMed Nakano S, Ito T, Furuya K et al (2004) Ambulatory blood pressure level rather than dipper/nondipper status predicts vascular events in type 2 diabetic subjects. Hypertens Res 27:647–656CrossRefPubMed
25.
go back to reference Leitao CB, Canani LH, Kramer CK, Boza JC, Pinotti AF, Gross JL (2007) Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients. Diabetes Care 30:1255–1260CrossRefPubMed Leitao CB, Canani LH, Kramer CK, Boza JC, Pinotti AF, Gross JL (2007) Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients. Diabetes Care 30:1255–1260CrossRefPubMed
26.
go back to reference Anan F, Masaki T, Umeno Y et al (2007) Correlations of urinary albumin excretion and atherosclerosis in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 77:414–419CrossRefPubMed Anan F, Masaki T, Umeno Y et al (2007) Correlations of urinary albumin excretion and atherosclerosis in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 77:414–419CrossRefPubMed
27.
go back to reference Tanaka M, Babazono T, Takeda M, Iwamoto Y (2006) Pulse pressure and chronic kidney disease in patients with type 2 diabetes. Hypertens Res 29:345–352CrossRefPubMed Tanaka M, Babazono T, Takeda M, Iwamoto Y (2006) Pulse pressure and chronic kidney disease in patients with type 2 diabetes. Hypertens Res 29:345–352CrossRefPubMed
28.
go back to reference Knudsen ST, Jeppesen P, Frederiksen CA et al (2007) Endothelial dysfunction, ambulatory pulse pressure and albuminuria are associated in type 2 diabetic subjects. Diabet Med 24:911–915CrossRefPubMed Knudsen ST, Jeppesen P, Frederiksen CA et al (2007) Endothelial dysfunction, ambulatory pulse pressure and albuminuria are associated in type 2 diabetic subjects. Diabet Med 24:911–915CrossRefPubMed
29.
go back to reference Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001). JAMA 285:2486–2497 Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001). JAMA 285:2486–2497
30.
go back to reference Parvanova AI, Trevisan R, Iliev IP et al (2006) Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 55:1456–1462CrossRefPubMed Parvanova AI, Trevisan R, Iliev IP et al (2006) Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 55:1456–1462CrossRefPubMed
31.
go back to reference Franciosi M, Pellegrini F, Sacco M et al (2007) Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic study. Clin J Am Soc Nephrol 2:984–991CrossRefPubMed Franciosi M, Pellegrini F, Sacco M et al (2007) Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic study. Clin J Am Soc Nephrol 2:984–991CrossRefPubMed
32.
go back to reference Pascual JM, Rodilla E, Gonzalez C, Perez-Hoyos S, Redon J (2005) Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension 45:1125–1130CrossRefPubMed Pascual JM, Rodilla E, Gonzalez C, Perez-Hoyos S, Redon J (2005) Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension 45:1125–1130CrossRefPubMed
33.
go back to reference Meigs JB, D’Agostino RB Sr, Nathan DM, Rifai N, Wilson PW (2002) Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care 25:977–983CrossRefPubMed Meigs JB, D’Agostino RB Sr, Nathan DM, Rifai N, Wilson PW (2002) Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care 25:977–983CrossRefPubMed
34.
go back to reference Colagiuri S, Cull CA, Holman RR (2002) Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care 25:1410–1417CrossRefPubMed Colagiuri S, Cull CA, Holman RR (2002) Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care 25:1410–1417CrossRefPubMed
35.
go back to reference Tapp RJ, Shaw JE, Zimmet PZ et al (2004) Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 44:792–798CrossRefPubMed Tapp RJ, Shaw JE, Zimmet PZ et al (2004) Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 44:792–798CrossRefPubMed
36.
go back to reference Wang XL, Lu JM, Pan CY, Tian H, Li CL (2005) A comparison of urinary albumin excretion rate and microalbuminuria in various glucose tolerance subjects. Diabet Med 22:332–335CrossRefPubMed Wang XL, Lu JM, Pan CY, Tian H, Li CL (2005) A comparison of urinary albumin excretion rate and microalbuminuria in various glucose tolerance subjects. Diabet Med 22:332–335CrossRefPubMed
37.
go back to reference Chen J, Muntner P, Hamm LL et al (2004) The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167–174PubMed Chen J, Muntner P, Hamm LL et al (2004) The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167–174PubMed
38.
go back to reference Bonnet F, Marre M, Halimi JM et al (2006) Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens 24:1157–1163CrossRefPubMed Bonnet F, Marre M, Halimi JM et al (2006) Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens 24:1157–1163CrossRefPubMed
39.
go back to reference de Boer IH, Sibley SD, Kestenbaum B et al (2007) Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 18:235–243CrossRefPubMed de Boer IH, Sibley SD, Kestenbaum B et al (2007) Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 18:235–243CrossRefPubMed
40.
go back to reference Tseng CH (2005) Waist-to-height ratio is independently and better associated with urinary albumin excretion rate than waist circumference or waist-to-hip ratio in Chinese adult type 2 diabetic women but not men. Diabetes Care 28:2249–2251CrossRefPubMed Tseng CH (2005) Waist-to-height ratio is independently and better associated with urinary albumin excretion rate than waist circumference or waist-to-hip ratio in Chinese adult type 2 diabetic women but not men. Diabetes Care 28:2249–2251CrossRefPubMed
41.
go back to reference Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483CrossRefPubMed Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483CrossRefPubMed
42.
go back to reference Rossing P, Rossing K, Gaede P, Pedersen O, Parving HH (2006) Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care 29:1024–1030CrossRefPubMed Rossing P, Rossing K, Gaede P, Pedersen O, Parving HH (2006) Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care 29:1024–1030CrossRefPubMed
43.
go back to reference Thomas MC, Rosengard-Barlund M, Mills V et al (2006) Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 29:317–322CrossRefPubMed Thomas MC, Rosengard-Barlund M, Mills V et al (2006) Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 29:317–322CrossRefPubMed
44.
go back to reference Tseng CH (2005) Lipid abnormalities associated with urinary albumin excretion rate in Taiwanese type 2 diabetic patients. Kidney Int 67:1547–1553CrossRefPubMed Tseng CH (2005) Lipid abnormalities associated with urinary albumin excretion rate in Taiwanese type 2 diabetic patients. Kidney Int 67:1547–1553CrossRefPubMed
45.
go back to reference Tseng CH (2005) Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int 68:796–801CrossRefPubMed Tseng CH (2005) Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int 68:796–801CrossRefPubMed
46.
go back to reference Drummond K, Mauer M (2002) The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51:1580–1587CrossRefPubMed Drummond K, Mauer M (2002) The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51:1580–1587CrossRefPubMed
47.
48.
go back to reference Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM (1998) Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 47:793–800CrossRefPubMed Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM (1998) Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 47:793–800CrossRefPubMed
49.
go back to reference Bilous R, Chaturvedi N, Sjolie AK et al (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151(11–20):W3–W4 Bilous R, Chaturvedi N, Sjolie AK et al (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151(11–20):W3–W4
50.
go back to reference Mann JF, Gerstein HC, Yi QL et al (2003) Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 14:641–647CrossRefPubMed Mann JF, Gerstein HC, Yi QL et al (2003) Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 14:641–647CrossRefPubMed
Metadata
Title
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
Authors
E. Ritz
G. C. Viberti
L. M. Ruilope
A. J. Rabelink
J. L. Izzo Jr
S. Katayama
S. Ito
A. Mimran
J. Menne
L. C. Rump
A. Januszewicz
H. Haller
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1577-3

Other articles of this Issue 1/2010

Diabetologia 1/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.